Alkermes PLC (ALKS) Earning Somewhat Favorable News Coverage, Analysis Shows
Media headlines about Alkermes PLC (NASDAQ:ALKS) have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alkermes PLC earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.509907662803 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Alkermes’ ARISTADA Shows Better Results to Treat Schizophrenia (finance.yahoo.com)
- Alkermes’ ARISTADA Shows Better Results to Treat Schizophrenia – Nasdaq (nasdaq.com)
- Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia (finance.yahoo.com)
- Patients Switched to Alkermes’ ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to … (tmcnet.com)
- Alkermes plc (ALKS) Says Patients Switched to its ARISTADA Showed Significant … (streetinsider.com)
A number of equities analysts recently commented on the company. ValuEngine upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Leerink Swann cut Alkermes PLC from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $68.00 to $61.00 in a research report on Tuesday, June 13th. Credit Suisse Group reissued a “buy” rating and issued a $70.00 price objective on shares of Alkermes PLC in a research report on Wednesday, June 7th. J P Morgan Chase & Co set a $78.00 price objective on Alkermes PLC and gave the company a “buy” rating in a research report on Saturday, July 1st. Finally, Zacks Investment Research raised Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. Alkermes PLC currently has an average rating of “Hold” and a consensus price target of $62.89.
Alkermes PLC (ALKS) opened at 50.37 on Friday. The firm’s 50 day moving average price is $51.49 and its 200 day moving average price is $56.44. The firm’s market cap is $7.74 billion. Alkermes PLC has a 52-week low of $41.93 and a 52-week high of $63.40.
Alkermes PLC (NASDAQ:ALKS) last posted its earnings results on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. The company had revenue of $218.80 million for the quarter, compared to analyst estimates of $216.54 million. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The company’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.01) earnings per share. Equities research analysts anticipate that Alkermes PLC will post ($0.04) EPS for the current fiscal year.
In other news, CAO Kathryn L. Biberstein sold 13,566 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $51.29, for a total value of $695,800.14. Following the completion of the transaction, the chief accounting officer now directly owns 70,455 shares of the company’s stock, valued at $3,613,636.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $50.77, for a total value of $76,155.00. Following the completion of the transaction, the director now directly owns 9,500 shares of the company’s stock, valued at $482,315. The disclosure for this sale can be found here. Insiders sold 18,066 shares of company stock valued at $941,485 over the last three months. Company insiders own 5.34% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Alkermes PLC (ALKS) Earning Somewhat Favorable News Coverage, Analysis Shows” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/24/alkermes-plc-alks-earning-somewhat-favorable-news-coverage-analysis-shows.html.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.